Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Sumitomo Dainippon Pharma Co Ltd    4506   JP3495000006

SUMITOMO DAINIPPON PHARMA CO LTD

(4506)
  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2020 467 B
EBIT 2020 69 362 M
Net income 2020 49 209 M
Finance 2020 153 B
Yield 2020 1,45%
Sales 2021 483 B
EBIT 2021 72 964 M
Net income 2021 52 429 M
Finance 2021 188 B
Yield 2021 1,41%
P/E ratio 2020 15,6x
P/E ratio 2021 14,6x
EV / Sales2020 1,32x
EV / Sales2021 1,20x
Capitalization 766 B
More Financials
Company
Dainippon Sumitomo Pharma Co. specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (90.8%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems... 
Sector
Pharmaceuticals
Calendar
07/29Earnings Release
More about the company
Surperformance© ratings of Sumitomo Dainippon Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on SUMITOMO DAINIPPON PHARMA
07/03SUMITOMO DAINIPPON PHARMA : Announces Discontinuation of Phase 3 CanStem111P Stu..
AQ
06/26Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results..
AQ
06/25SUMITOMO DAINIPPON PHARMA : DS Pharma Animal Health awards Hacarus the Grand Pri..
AQ
06/19Sumitomo Dainippon Pharma and Nitto Denko Announce the Approval of Atypical A..
AQ
06/17SUMITOMO DAINIPPON PHARMA : announces Personnel Changes
AQ
06/14SUMITOMO DAINIPPON PHARMA : announces Changes to Agreement on Joint Development ..
AQ
06/10SUMITOMO DAINIPPON PHARMA : Announces Recommendation to Continue Phase 3 CanStem..
AQ
05/31SUMITOMO DAINIPPON PHARMA : Sumitomo Dainippon Pharma Signs a Co-Promotion and S..
AQ
05/23SUMITOMO DAINIPPON PHARMA : to Launch RETHIO for Conditioning Treatment Prior to..
AQ
05/10SUMITOMO DAINIPPON PHARMA CO LTD : Annual results
CO
More news
Analyst Recommendations on SUMITOMO DAINIPPON PHARMA
More recommendations
Sector news : Pharmaceuticals - NEC
05:45aJOHNSON & JOHNSON : Faces Key Test in Defense Against Talc-Safety Lawsuits
DJ
07/19CELGENE : Says FDA Approves Otezla for Oral Ulcers in Behcet's Disease
DJ
07/19ALLERGAN : Form 8.3 -
DJ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/19JOHNSON & JOHNSON : J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in M..
DJ
More sector news : Pharmaceuticals - NEC
Chart SUMITOMO DAINIPPON PHARMA CO LTD
Duration : Period :
Sumitomo Dainippon Pharma Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMITOMO DAINIPPON PHARMA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 9
Average target price 2 080,00  JPY
Last Close Price 1 929,00  JPY
Spread / Highest target 65,9%
Spread / Average Target 7,83%
Spread / Lowest Target -27,4%
EPS Revisions
Managers
NameTitle
Hiroshi Nomura President & Representative Director
Masayo Tada Chairman
Yoshiharu Ikeda General Manager-Research Technology
Nobuyuki Hara Director, Executive Officer & GM-Development
Hitoshi Odagiri Director, Managing Executive Officer & GM-Sales
Sector and Competitors
1st jan.Capitalization (M$)
SUMITOMO DAINIPPON PHARMA CO LTD-43.18%7 114
JOHNSON & JOHNSON2.34%345 980
PFIZER-1.35%237 451
ROCHE HOLDING LTD.11.42%230 263
ROCHE HOLDING13.37%230 263
NOVARTIS24.46%216 273